MX2024008691A - Composiciones y metodos de triptamina. - Google Patents
Composiciones y metodos de triptamina.Info
- Publication number
- MX2024008691A MX2024008691A MX2024008691A MX2024008691A MX2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A MX 2024008691 A MX2024008691 A MX 2024008691A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- methods
- salt forms
- disorders
- tryptamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen sales farmacéuticamente aceptables de compuestos de triptamina, el uso de dichas formas de sal en el tratamiento de enfermedades asociadas con un receptor de serotonina 5-HT2, composiciones farmacéuticas tales como las adaptadas para la administración por inhalación que contienen las formas de sal, métodos para administrar las formas de sal farmacéuticamente aceptables (por ejemplo, por inhalación), y métodos de tratamiento de enfermedades o trastornos asociados con un receptor de serotonina 5-HT2, como trastornos del sistema nervioso central (CNS) o trastornos psicológicos, con las formas de sal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299599P | 2022-01-14 | 2022-01-14 | |
| US202263384704P | 2022-11-22 | 2022-11-22 | |
| PCT/EP2023/050702 WO2023135237A1 (en) | 2022-01-14 | 2023-01-13 | Tryptamine compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008691A true MX2024008691A (es) | 2024-07-19 |
Family
ID=85018123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008691A MX2024008691A (es) | 2022-01-14 | 2023-01-13 | Composiciones y metodos de triptamina. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250051279A1 (es) |
| EP (1) | EP4463440A1 (es) |
| JP (1) | JP2025502208A (es) |
| KR (1) | KR20240134951A (es) |
| AU (1) | AU2023207801A1 (es) |
| CA (1) | CA3259235A1 (es) |
| IL (1) | IL313889A (es) |
| MX (1) | MX2024008691A (es) |
| WO (1) | WO2023135237A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023383549A1 (en) | 2022-11-17 | 2025-06-05 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| ID28302A (id) | 1999-01-14 | 2001-05-10 | Teijin Ltd | Alat untuk mengumpankan suatu bubuk dalam jumlah tertentu |
| GB0121568D0 (en) | 2001-09-06 | 2001-10-24 | Optinose As | Nasal delivery device |
| ATE514445T1 (de) | 1999-03-03 | 2011-07-15 | Optinose As | Nasales verabreichungsgerät |
| GB0114272D0 (en) | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
| GB0019715D0 (en) | 2000-08-10 | 2000-09-27 | Pa Consulting Services | Device for delivering physiologically active agent in powdered form |
| ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
| WO2003026559A2 (en) | 2001-09-28 | 2003-04-03 | Kurve Technology, Inc | Nasal nebulizer |
| GB0207422D0 (en) | 2002-03-28 | 2002-05-08 | Optinose As | Nasal devices |
| GB0207817D0 (en) | 2002-04-04 | 2002-05-15 | Optinose As | Nasal devices |
| GB0209494D0 (en) | 2002-04-25 | 2002-06-05 | Optinose As | Nasal devices |
| US7267121B2 (en) | 2004-04-20 | 2007-09-11 | Aerogen, Inc. | Aerosol delivery apparatus and method for pressure-assisted breathing systems |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| PH12022553135A1 (en) * | 2020-05-19 | 2024-03-04 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) * | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| RU199823U1 (ru) | 2020-06-10 | 2020-09-21 | Общество С Ограниченной Ответственностью "Центр Передовых Радиационных Медицинских И Биологических Технологий | Устройство для лечения бронхолегочных заболеваний |
| CA3194558A1 (en) * | 2020-10-02 | 2022-04-07 | Brett J. GREENE | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
-
2023
- 2023-01-13 MX MX2024008691A patent/MX2024008691A/es unknown
- 2023-01-13 WO PCT/EP2023/050702 patent/WO2023135237A1/en not_active Ceased
- 2023-01-13 AU AU2023207801A patent/AU2023207801A1/en active Pending
- 2023-01-13 EP EP23700949.3A patent/EP4463440A1/en active Pending
- 2023-01-13 JP JP2024541809A patent/JP2025502208A/ja active Pending
- 2023-01-13 US US18/720,922 patent/US20250051279A1/en active Pending
- 2023-01-13 IL IL313889A patent/IL313889A/en unknown
- 2023-01-13 CA CA3259235A patent/CA3259235A1/en active Pending
- 2023-01-13 KR KR1020247026687A patent/KR20240134951A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL313889A (en) | 2024-08-01 |
| AU2023207801A1 (en) | 2024-06-27 |
| EP4463440A1 (en) | 2024-11-20 |
| US20250051279A1 (en) | 2025-02-13 |
| CA3259235A1 (en) | 2023-07-20 |
| KR20240134951A (ko) | 2024-09-10 |
| WO2023135237A1 (en) | 2023-07-20 |
| JP2025502208A (ja) | 2025-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bersani et al. | 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo | |
| CA3244130A1 (en) | PHENETYLAMINE DERIVATIVES, COMPOSITIONS AND METHODS OF USE | |
| IS7891A (is) | Skiptitengd þrísýklísk gamma-karbólín sem serótónín viðtaka gerandefni og mótverkunarefni | |
| WO2000010551A3 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| SI1678172T1 (sl) | AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| MX2021007322A (es) | Formulaciones farmaceuticas que contienen relacorilant, un compuesto de azadecalina fusionado con heteroaril-cetona. | |
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| JPH08183735A (ja) | 不安症の治療 | |
| MX2024011170A (es) | Compuestos organicos. | |
| MX2024008691A (es) | Composiciones y metodos de triptamina. | |
| WO2002004456A1 (en) | SUBSTITUTED 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINO[4,5-b]PYRANO[3,2-e]INDOLES | |
| ZA202404599B (en) | Heteroalicyclic derivatives and their use in the treatment of cns disorders | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| EP1007046A1 (en) | 1h-indole-3-glyoxylamides for the treatment of chronic bronchitis | |
| JPH11501051A (ja) | 強迫性障害、睡眠時無呼吸、性的機能障害、嘔吐および乗物酔いの処置を意図する医薬 | |
| TW200631956A (en) | Azabenzoxazoles for the treatment of CNS disorders | |
| ES2815555T3 (es) | Triple combinación de antagonistas del receptor 5-HT6 puros, inhibidores de la acetilcolinesterasa y antagonista del receptor NMDA | |
| MX2023009285A (es) | Compuestos novedosos. | |
| JP2005513105A (ja) | 臨床的うつ病を治療するためのデオキシペガニンの使用 | |
| AU2017311666B2 (en) | Triple combination of histamine-3 receptor inverse agonists, acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| ES2810983T3 (es) | Combinación de agonistas inversos del receptor de histamina-3 con inhibidores de acetilcolinesterasa | |
| ZA202405718B (en) | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders | |
| MX2025002007A (es) | Compuestos heteroaromaticos para el tratamiento de trastornos neurologicos |